Do you want to read an article? Please log in or register.
Long-term efficacy and safety of biosimilar infliximab (CT-P13) after switching from originator infliximab: Open-label extension of the NOR-SWITCH trial
Inflammatory Bowel Disease
Related content
Inflammatory Bowel Disease
Serum concentrations after switching from originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease (SECURE): an open-label, multicentre, phase 4 non-inferiority trial
Lancet Gastroenterol Hepatol.
Strik AS, van de Vrie W, Bloemsaat-Minekus JPJ, Nurmohamed M, Bossuyt PJJ, Bodelier A, Rispens T, van Megen YJB, D'Haens GR
doi: 10.1016/S2468-1253
RECOMMENDED
Gallbladder and Biliary Diseases
Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: 3-year results of an international open-label extension study
Lancet Gastroenterol Hepatol.
Trauner M, Nevens F, Shiffman ML, Drenth JPH, Bowlus CL, Vargas V, Andreone P, Hirschfield GM, Pencek R, Malecha ES, MacConell L, Shapiro D
doi: 10.1016/S2468-1253(19)30094-9.
COMMENTED
Esophagus Diseases
Long-term Efficacy and Tolerability of RPC4046 in an Open-Label Extension Trial of Patients With Eosinophilic Esophagitis
★ 3
Recommended and commented by
Prof. Dr Stephan Vavricka, Faculty Member
doi: 10.1016/j.cgh.2020.03.036.
Inflammatory Bowel Disease
Long-Term Safety and Efficacy of Risankizumab Treatment in Patients with Crohn's Disease: Results from the Phase 2 Open-Label Extension Study
J Crohns Colitis
Ferrante M, Feagan BG, Panés J, Baert F, Louis E, Dewit O, Kaser A, Duan WR, Pang Y, Lee WJ, Gustafson D, Liao X, Wallace K, Kalabic J, D'Haens GR
doi: 10.1093/ecco-jcc/jjab093
COMMENTED
Inflammatory Bowel Disease
Long-Term Efficacy And Safety Of Ozanimod In Moderate-To-Severe Ulcerative Colitis: Results From The Open-Label Extension Of The Randomized, Phase 2 Touchstone Study
★ 3
Recommended and commented by
PD Dr Luc Biedermann, Faculty Member
J Crohns Colitis
Sandborn WJ, Feagan BG, Hanauer S, Vermeire S, Ghosh S, Liu WJ, Petersen A, Charles L, Huang V, Usiskin K, Wolf DC, D'Haens G
doi: 10.1093/ecco-jcc/jjab012
Inflammatory Bowel Disease
The SPOSIB SB2 Sicilian Cohort: Safety and Effectiveness of Infliximab Biosimilar SB2 in Inflammatory Bowel Diseases, Including Multiple Switches
Inflamm Bowel Dis.
Macaluso FS, Fries W, Viola A, Centritto A, Cappello M, Giuffrida E, Privitera AC, Piccillo G, Magnano A, Vinci E, Vassallo R, Trovatello A, Belluardo N, Giangreco E, Camilleri S, Garufi S, Bertolami C, Ventimiglia M, Renna S, Orlando R, Rizzuto G, Orlando A
doi: 10.1093/ibd/izaa036.
Inflammatory Bowel Disease
Switching to a infliximab biosimilar: short-term results of clinical monitoring in patients with inflammatory bowel disease
Eur J Gastroenterol Hepatol.
Binkhorst L, Sobels A, Stuyt R, Westerman EM, West RL
doi: 10.1097/
Inflammatory Bowel Disease
Effectiveness and Safety of Adalimumab Biosimilar SB5 in IBD: Outcomes in Originator to SB5 Switch, Double Biosimilar Switch and Bio-Naieve SB5 Observational Cohorts
J Crohns Colitis
Derikx LAAP, Dolby HW, Plevris N, Lucaciu L, Rees CS, Lyons M, Siakavellas SI, Constantine-Cooke N, Jenkinson P, Su S, O'Hare C, Kirckpatrick L, Merchant LM, Noble C, Arnott ID, Jones GR, Lees CW
doi: 10.1093/ecco-jcc/jjab100
Helicobacter Pylori
Long-term changes of gut microbiota, antibiotic resistance, and metabolic parameters after Helicobacter pylori eradication: a multicentre, open-label, randomised trial
Lancet Infect Dis.
Liou JM, Chen CC, Chang CM, Fang YJ, Bair MJ, Chen PY, Chang CY, Hsu YC, Chen MJ, Chen CC, Lee JY, Yang TH, Luo JC, Chen CY, Hsu WF, Chen YN, Wu JY, Lin JT, Lu TP, Chuang EY, El-Omar EM, Wu MS, Taiwan Gastrointestinal Disease and Helicobacter Consortium.
doi: 10.1016/S1473-3099(19)30272-5.